Peptide Based Hematological Disorders Therapeutics Market: Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022

Fact.MR has added a new report, titled "Peptide Based Hematological Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022" to its database of market report. The global peptide based hematological disorders therapeutics market is slated to touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

4 Forecast Highlights on Global Peptide Based Hematological Disorders Therapeutics Market

As per the forecast of Fact.MR, the ecallantide segment is slated to touch a value of nearly US$ 120 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The ecallantide segment is estimated to account for more than one-fifth of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=189

As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 115 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.

As per the forecast of Fact.MR, by the end of 2022, North America peptide based hematological disorders therapeutics market is projected to reach nearly US$ 220 Mn, registering a robust CAGR over the forecast period.
As perFact.MR forecasts, the US peptide based hematological disorders therapeutics market is estimated to account for 88.6% revenue share of the global peptide based hematological disorders therapeutics market by 2017 end and is expected to gain in market share by 2022 over 2017.

The report has also profiled leading players in the global market for peptide based hematological disorders therapeutics, which will remain active through 2022. These include companies such as Shire plc.

Browse Full Report with TOC- https://www.factmr.com/report/189/peptide-based-hematological-disorders-therapeutics-market

Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes Shire plc.

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.